Related Experiment Video

Updated: Oct 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MicroRNA-337-3p impedes breast cancer progression by targeting cyclin-dependent kinase 1

Shuxin Kong1, Jianyang Liu2, Bin Zhang1

  • 1Department of Breast Surgery, The People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China.

Oncology Letters
|November 25, 2021
PubMed

Insights

MicroRNAs (miRNAs) regulate breast cancer (BC). Low levels of miR-337-3p suppress BC progression by targeting cyclin-dependent kinase 1 (CDK1), indicating a tumor-suppressive role.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are crucial regulators in various cancers, including breast cancer (BC).
  • Dysregulation of specific miRNAs can significantly impact BC development and progression.
  • Understanding miRNA functions is vital for identifying novel therapeutic targets in BC.

Purpose of the Study:

  • To investigate the role and molecular mechanism of miR-337-3p in breast cancer cells.
  • To identify key regulatory genes and miRNAs associated with BC progression.
  • To elucidate the relationship between miR-337-3p and its potential target gene, CDK1.

Main Methods:

  • Bioinformatics analysis to identify key regulatory molecules in BC.
  • Quantitative PCR and Western blot to assess RNA and protein expression levels.
  • Cell proliferation, adhesion, and apoptosis assays to evaluate BC cell behavior.
  • Dual-luciferase reporter and RNA pull-down assays to confirm miRNA-mRNA interactions.

Main Results:

  • miR-337-3p was found to be downregulated in BC cells and tissues, suppressing tumor progression.
  • Cyclin-dependent kinase 1 (CDK1) was upregulated in BC, correlating with increased proliferation and adhesion, and decreased apoptosis.
  • miR-337-3p directly targets CDK1, thereby inhibiting BC cell progression.

Conclusions:

  • miR-337-3p exhibits a tumor-suppressive function in breast cancer.
  • The miR-337-3p/CDK1 axis represents a potential therapeutic target for BC treatment.
Keywords:
breast cancercyclin-dependent kinase 1microRNA-337-3p

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.5K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.1K